Topics:
Gynecologic Cancers • Medical Oncology
After seeing results from GOG238, is there a subset of patients that might still benefit from chemoradiation for centrally recurrent endometrial cancer?
For example, do you think young patients might potentially benefit from the addition of cisplatin, knowing the average age in this study was 65.
Answer from: Radiation Oncologist at Community Practice
It’s hard to know who would benefit but use for bulky or high grade central recurrence. Bulky is subjective but usually for lesions that are more likely to need interstitial brachytherapy.
Sign in or Register to read more